An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to ...